Drug Trial Radar · NCT06748079
A Clinical Study of TQC3721 Inhalation Powder in Patients With Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Dec 3, 2024
Primary completion
Aug 7, 2026
Study completion Aug 7, 2026
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, dose escalation, multicenter study design. The purpose is to evaluate the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of TQC3721 inhalation powder in Chronic Obstructive Pulmonary Disease(COPD) patients with single/multiple dose escalation.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TQC3721 inhalation powderDrug
TQC3721 is a target inhibitor.
Placebo for TQC3721 inhalation powderDrug
Placebo without drug substance.
TQC3721 inhalation powder combined with glyberlam inhalation powder or a control groupDrug
TQC3721 is a target inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE)Time frame: 21 days
- Serious Adverse Events (SAE)Time frame: 21 days
- Treatment-emergent adverse events (TEAEs)Time frame: 19 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.